Skip to content
drillr.ai
Sign up

NOVN.CH

Novartis AG

Healthcare · Drug Manufacturers - General · CH

Also listed · NVS →
—
Ask drillr

  • Sep 11, 2026, 13:56 UTC

    Novartis shares slumped 11% in one day, wiping nearly $30 billion off its market value, after the failure of the muscle-wasting disorder drug del-desiran in a late-stage study.

    Source:

  • Sep 11, 2026, 03:55 UTC

    In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

    Source:

  • Sep 10, 2026, 21:07 UTC

    Whitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.

  • Sep 10, 2026, 11:50 UTC

    Artisan Partners, a shareholder of Novartis AG, publicly urged the Swiss drugmaker to shake up its board and overhaul its M&A approach after share declines following three clinical trial setbacks.

    Source:

  • Sep 10, 2026, 10:22 UTC

    A major shareholder in Novartis called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall following back-to-back drug trial setbacks.

    Source:

  • Sep 10, 2026, 08:59 UTC

    Palantir Technologies hosted its eleventh AIPCon event in Miami, featuring customer presentations on AI applications.

    Source:

  • Sep 4, 2026, 21:20 UTC

    Ionis Pharmaceuticals and partner Novartis announced on Friday that their experimental heart drug failed in a late-stage trial.

    Source:

  • Sep 4, 2026, 21:07 UTC

    Novartis announced that its experimental cardiovascular drug pelacarsen failed to reduce cardiovascular risk in the Phase 3 HORIZON trial.

    Source:

  • Sep 2, 2026, 12:37 UTC

    Novartis plans to cease production at its Kleinhüningen site in Basel, potentially eliminating about 130 jobs, subject to information and consultation procedures.

    Source:

  • Sep 2, 2026, 12:12 UTC

    South Korea's Alteogen signed a deal with Swiss drugmaker Novartis worth up to $3.22 billion, granting Novartis access to Alteogen's technology for making injectable versions of intravenous drugs.

    Source:

  • Sep 1, 2026, 07:13 UTC

    Novartis announced that its oral drug remibrutinib met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.

    Source:

  • Sep 1, 2026, 04:14 UTC

    Novartis paused eight clinical trials of an experimental cell therapy for autoimmune and neurological disorders in late August 2026 after three patient deaths.

    Source:

  • Aug 29, 2026, 07:32 UTC

    Novartis presented Phase 2 TRANQUILITY study results at the European Society of Cardiology annual meeting in Munich, showing its drug pacibekitug reduced inflammation biomarkers in a dose-dependent manner.

    Source:

  • Aug 28, 2026, 00:18 UTC

    China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

    Source:

  • Aug 25, 2026, 13:43 UTC

    Novartis announced that China's National Medical Products Administration (NMPA) approved its radioligand therapy drug Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for a new indication in metastatic hormone-sensitive prostate cancer patients.

    Source:

  • Aug 20, 2026, 10:04 UTC

    Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.

    Source:

  • Aug 18, 2026, 13:25 UTC

    Novartis announced it will not pursue reimbursement in Canada for Vanrafia, its newly approved treatment for a rare kidney disease, due to the current access environment.

    Source:

  • Aug 18, 2026, 12:23 UTC

    On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.

    Source:

  • Aug 13, 2026, 13:56 UTC

    Novartis defeated a UK court bid by Accord Healthcare to invalidate its patent for the heart drug Entresto, with London's High Court rejecting the claim.

    Source:

  • Aug 10, 2026, 15:11 UTC

    The U.S. Food and Drug Administration rejected ITM Isotope Technologies Munich SE's radiopharmaceutical therapy ITM-11 due to manufacturing issues, preventing it from becoming a competitor to Novartis' treatment.

    Source:

  • Aug 4, 2026, 21:33 UTC

    Swiss pharmaceutical company Novartis announced a $23 billion investment in 10 different U.S. manufacturing and research & development facilities, creating 4,000 jobs.

    Source:

  • Aug 3, 2026, 17:46 UTC

    The Swiss Market Index (SMI) closed marginally up on Monday, with Logitech International and Sonova leading gains, while Sandoz Group and Holcim declined.

    Source:

  • Jul 31, 2026, 20:26 UTC

    Novartis announced that its drug Pluvicto received FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer, potentially advancing a new standard of care for metastatic prostate cancer.

    Source:

  • Jul 31, 2026, 14:13 UTC

    Novartis's sacubitril/valsartan sodium tablets were selected in the 12th batch of China's national centralized drug procurement, covering the heart failure indication.

    Source:
Page 1Next →